To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cas No.: | 461432-26-8 |
| SMILES: | O[C@H]1[C@H](C2=CC=C(Cl)C(CC3=CC=C(OCC)C=C3)=C2)O[C@H](CO)[C@@H](O)[C@@H]1O |
| Formula: | C21H25ClO6 |
| M.Wt: | 408.87 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Dapagliflozin (BMS-512148) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. |
| In Vivo: | At 11 mM glucose, dapagliflozin raises glucagon release from 18% to 32% of control, while the effect of dapagliflozin addition is minor at 1 mM glucose. At the intermediate glucose concentration of 6 mM, glucagon secretion is estimated to be 24% and 30% of control in the absence or presence of dapagliflozin, respectively[1]. Dapagliflozin pretreatment significantly reduces the number of TUNEL-positive cells in IR-injured kidneys. Dapagliflozin pretreatment significantly elevates the HIF1 expression in IR-injured renal tubular cells from mice[2]. Dapagliflozin (10 mg/kg, o.p.) causes a marked increase in urinary glucose in SGLT2i-mice. Dapagliflozin acutely suppresses BAT thermogenesis by reducing sympathetic nerve activity. Dapagliflozin enhances hepatic gluconeogenesis and glycogenolysis[3]. |
| In Vitro: | Dapagliflozin pretreatment of hypoxic HK2 cells significantly improves the cell viability in a dose-dependent manner. Dapagliflozin decreases Bax expression, the Bax/Bcl2 ratio, and PARP expression in hypoxic HK2 cells[2]. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|